ZURICH (Reuters) – Novartis will cut up to 680 jobs in the development sector, which helps bring its drugs to market, the Swiss pharmaceutical group said on Tuesday.
Around 440 jobs will be lost in Switzerland and up to 240 in the United States over the next two or three years, the Basel company said.
These layoffs are separate from a restructuring program which could subsequently result in the elimination of 8,000 positions out of Novartis’ 78,000 employees worldwide, the group added.
Its Swiss rival Roche also announced at the start of the year the elimination of 345 jobs in the same sector.
Novartis currently employs approximately 12,500 people in development, which includes drug regulatory management, analysis and quality assurance.
Around 3,000 of these positions are currently in Switzerland and 2,000 in the United States, meaning that around 14% of positions in these countries will be affected.
At the same time, the company said it would add positions over the next two to three years.
(Reporting John Revill; Federica Mileo, editing by Kate Entringer)
Copyright © 2024 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
